Baidu
map

KSQ Therapeutics发现潜在活性优于PD-1的基因靶标,可用于开发针对性的工程化肿瘤浸润淋巴细胞(eTIL)治疗难治性实体瘤

2020-02-11 不详 MedSci原创

生物技术公司KSQ Therapeutics使用其专有的CRISPRomics发现平台来系统筛选整个基因组,以鉴定肿瘤学和自身免疫性疾病的最佳基因靶标,今天宣布新型靶标CT-1可开发用于工程化肿瘤浸润淋巴细胞(eTIL?)治疗难治性实体瘤。

生物技术公司KSQ Therapeutics使用其专有的CRISPRomics发现平台来系统筛选整个基因组,以鉴定肿瘤学和自身免疫性疾病的最佳基因靶标,今天宣布新型靶标CT-1可开发用于工程化肿瘤浸润淋巴细胞(eTIL)治疗难治性实体瘤。

KSQ Therapeutics首席科学官Frank Stegmeier说:"长期以来,人们一直认为采用过继性细胞疗法可以治疗难治性实体瘤,但其有效性受到免疫抑制性肿瘤微环境的限制。CRISPRomics平台使我们能够鉴定可提高T细胞在抑制性肿瘤微环境中发挥功能的基因靶标。这些发现将促进我们开发出一系列CRISPR/Cas9 eTIL药物,有可能改变过继细胞PD-1难治性实体瘤的治疗"。

KSQ专有的CRISPRomics平台用于识别T细胞基因组中的主要靶标,从而提高PD-1难治性小鼠实体瘤模型中过继T细胞转移疗法(ACT)的功效。KSQ识别的未公开靶标CT-1成为头号目标。CT-1编辑的T细胞在体内产生的抗肿瘤活性增加了10倍,而CT-1编辑的人类TIL则显示出增强的细胞因子应答。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-02-13 piaojinhua
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-12-28 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-02-13 zhaojie88
  9. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-02-13 freve
  10. [GetPortalCommentsPageByObjectIdResponse(id=1930205, encodeId=b8901930205c5, content=<a href='/topic/show?id=2a3410581e3' target=_blank style='color:#2F92EE;'>#KSQ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10581, encryptionId=2a3410581e3, topicName=KSQ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Thu Feb 13 05:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Aug 10 19:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728296, encodeId=1a331e2829620, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Dec 28 02:32:00 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974390, encodeId=817419e439074, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Aug 10 10:32:00 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818921, encodeId=6bd818189218c, content=<a href='/topic/show?id=8ecf9861814' target=_blank style='color:#2F92EE;'>#难治性实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98618, encryptionId=8ecf9861814, topicName=难治性实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Nov 15 07:32:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302299, encodeId=e704130229917, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350840, encodeId=2ec913508408e, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352852, encodeId=71a81352852d4, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528641, encodeId=50941528641f1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Feb 13 03:32:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379148, encodeId=ca123e914867, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hVpkYy8lg1kItvlriavHzhx4l36BwvxzOPgZABcEW7lwvrq3ibEKBNtvjpEgzGa9StMWB79jPNkz6zosChP7wq7g/132, createdBy=46805277400, createdName=土豆2995, createdTime=Wed Feb 12 13:01:44 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-02-12 土豆2995

    厉害

    0

Baidu
map
Baidu
map
Baidu
map